To date, scRNA studies have revealed several new targets in lung cancer and brought new treatment options to immunotherapy such as TREM2+, SPP1+ and C1Q+ TAMs, which are associated with the malignant progression of lung cancer. Here, SPP1 is linked to lung carcinoma.